Gland Pharma · NSE: GLAND · BSE: 543245
Q1 FY24 results · Apr–Jun 2023
Gland Pharma reported revenue from operations of ₹1,208.69 crore (up 41.1% from Q1 FY23) and net profit of ₹194.10 crore (down 15.3% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,208.69 | 856.90 | +41.1% | 785.01 | +54.0% |
| Other income | 37.54 | 74.39 | −49.5% | 38.94 | −3.6% |
| Total income | 1,246.23 | 931.29 | +33.8% | 823.95 | +51.3% |
| Profit before tax | 261.27 | 308.50 | −15.3% | 111.15 | +135.1% |
| Net profit for the period | 194.10 | 229.17 | −15.3% | 78.68 | +146.7% |
| EPS, basic (₹) | 11.79 | 13.93 | −15.4% | 4.78 | +146.7% |
| Net margin (%) | 16.1 | 26.7 | 10.0 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 884.07 | 856.90 | +3.2% | 785.42 | +12.6% |
| Other income | 35.21 | 74.39 | −52.7% | 38.94 | −9.6% |
| Total income | 919.28 | 931.29 | −1.3% | 824.36 | +11.5% |
| Profit before tax | 253.99 | 308.78 | −17.7% | 111.91 | +127.0% |
| Net profit for the period | 187.58 | 229.45 | −18.2% | 79.21 | +136.8% |
| EPS, basic (₹) | 11.39 | 13.95 | −18.4% | 4.81 | +136.8% |
| Net margin (%) | 21.2 | 26.8 | 10.1 |
Consolidated
- Filed with BSE
- 07 Aug 2023, 19:58 IST
- Board meeting
- 07 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Aug 2023, 19:58 IST
- Board meeting
- 07 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE